EP0788375A3 - - Google Patents
Info
- Publication number
- EP0788375A3 EP0788375A3 EP95944855A EP95944855A EP0788375A3 EP 0788375 A3 EP0788375 A3 EP 0788375A3 EP 95944855 A EP95944855 A EP 95944855A EP 95944855 A EP95944855 A EP 95944855A EP 0788375 A3 EP0788375 A3 EP 0788375A3
- Authority
- EP
- European Patent Office
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Polyethers (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33685094A | 1994-11-09 | 1994-11-09 | |
| US336850 | 1994-11-09 | ||
| US39469095A | 1995-02-23 | 1995-02-23 | |
| US394690 | 1995-02-23 | ||
| PCT/IB1995/001175 WO1996041813A2 (en) | 1994-11-09 | 1995-11-09 | Functionalized polymers for site-specific attachment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0788375A2 EP0788375A2 (en) | 1997-08-13 |
| EP0788375A3 true EP0788375A3 (oth) | 1997-09-17 |
Family
ID=26990408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP95944855A Withdrawn EP0788375A2 (en) | 1994-11-09 | 1995-11-09 | Functionalized polymers for site-specific attachment |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0788375A2 (oth) |
| AU (1) | AU7327296A (oth) |
| CA (1) | CA2204726A1 (oth) |
| WO (1) | WO1996041813A2 (oth) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100361933B1 (ko) | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트 |
| GB9525955D0 (en) * | 1995-12-19 | 1996-02-21 | Therexsys Ltd | Improved pharmaceutical compositions |
| US5830852A (en) * | 1995-12-19 | 1998-11-03 | Cobra Therapeutics, Ltd. | Compositions for insulin-receptor mediated nucleic acid delivery |
| CN1161127C (zh) | 1997-07-03 | 2004-08-11 | 奥奎斯特公司 | 交联的多糖药物载体 |
| FI980489A7 (fi) * | 1998-03-04 | 1999-09-05 | Alexei Radievich Khomutov | Syklodekstriinien uudet johdannaiset |
| JP4593048B2 (ja) | 1999-12-24 | 2010-12-08 | 協和発酵キリン株式会社 | 分岐型ポリアルキレングリコール類 |
| AU782580B2 (en) | 2000-01-10 | 2005-08-11 | Maxygen, Inc. | G-CSF conjugates |
| ATE428445T1 (de) | 2000-02-11 | 2009-05-15 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| US6608198B2 (en) | 2000-03-30 | 2003-08-19 | Abbott Laboratories | Crystalline pharmaceutical |
| EP1292337A2 (en) | 2000-06-08 | 2003-03-19 | La Jolla Pharmaceutical | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| HK1056113A1 (zh) * | 2000-06-30 | 2004-02-06 | Smithkline Beecham Corporation | 趋化因子共轭物 |
| JP2004508338A (ja) * | 2000-09-08 | 2004-03-18 | グリフォン セラピューティクス，インコーポレーテッド | ポリマー修飾合成タンパク質 |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| UY26929A1 (es) * | 2000-09-29 | 2002-04-26 | Abbott Lab | Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis |
| WO2002043770A2 (en) * | 2000-12-01 | 2002-06-06 | Conforma Therapeutic Corporation | Homing peptide multimers, their preparation and uses |
| ES2361824T3 (es) | 2000-12-20 | 2011-06-22 | F. Hoffmann-La Roche Ag | Conjugados de eritropoyetina (epo) con polietilenglicol (peg). |
| BR0207576A (pt) | 2001-02-27 | 2004-04-27 | Maxygen Aps | Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
| PT1517710E (pt) | 2002-06-21 | 2011-07-08 | Novo Nordisk Healthcare Ag | Glicoformas do factor vii peguilado |
| EP1549350B1 (en) | 2002-10-08 | 2008-09-24 | Fresenius Kabi Deutschland GmbH | Pharmaceutically active oligosaccharide conjugates |
| AU2003292632A1 (en) | 2002-12-26 | 2004-07-22 | Shionogi Co., Ltd. | Method of purifying/concentrating sugar chain with sugar chain-trapping molecule and method of analyzing sugar chain structure |
| BRPI0407882B1 (pt) | 2003-02-26 | 2021-07-27 | Nektar Therapeutics | Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação |
| US20040249119A1 (en) * | 2003-06-05 | 2004-12-09 | Fox Martin Edward | Novel mPEG propionaldehyde precursor |
| US20080206182A1 (en) * | 2003-08-08 | 2008-08-28 | Fresenius Kabi Deutschland Gmbh | Conjugates of a Polymer and a Protein Linked by an Oxime Group |
| WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| US20060228331A1 (en) | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
| CN102516386A (zh) | 2003-10-10 | 2012-06-27 | 诺沃挪第克公司 | Il-21衍生物 |
| ES2428358T3 (es) | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
| EP2033662B1 (en) | 2004-01-21 | 2012-10-17 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
| US20130302877A1 (en) * | 2004-01-29 | 2013-11-14 | Fina Biosolutions Llc | Differential Functionalization of Polymers with Amino-Oxy Reagents for Diagnostic Assays |
| CA2553035A1 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| JP2008503217A (ja) | 2004-06-18 | 2008-02-07 | アンブレツクス・インコーポレイテツド | 新規抗原結合ポリペプチド及びそれらの使用 |
| EP1771573A4 (en) | 2004-07-21 | 2009-02-18 | Ambrx Inc | BIOSYNTHETIC POLYPEPTIDES OBTAINED FROM NON-NATURALLY CITED AMINO ACIDS |
| US7632921B2 (en) | 2004-11-12 | 2009-12-15 | Bayer Healthcare Llc | Site-directed modification of FVIII |
| BRPI0519170A8 (pt) | 2004-12-22 | 2018-05-08 | Ambrx Inc | formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado |
| CN102732588B (zh) | 2004-12-22 | 2015-01-07 | Ambrx公司 | 氨酰基-tRNA合成酶的组合物及其用途 |
| BRPI0518661A2 (pt) | 2004-12-22 | 2008-12-02 | Ambrx Inc | mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante |
| ATE542920T1 (de) | 2004-12-22 | 2012-02-15 | Ambrx Inc | Modifiziertes menschliches wachstumshormon |
| SG158186A1 (en) | 2004-12-22 | 2010-01-29 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| WO2006133089A2 (en) | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| MX2008002149A (es) | 2005-08-18 | 2008-04-22 | Ambrx Inc | Composiciones de arnt y sus usos. |
| RU2008105545A (ru) * | 2005-08-30 | 2009-10-10 | Ново Нордиск Хелс Кеа Аг (Ch) | Жидкие препараты пэгилированного гормона роста |
| PT1954710E (pt) | 2005-11-08 | 2011-06-07 | Ambrx Inc | Aceleradores para a modificação de aminoácidos nãonaturais e polipeptídeos de aminoácidos não-naturais |
| CN101454461A (zh) | 2005-11-16 | 2009-06-10 | Ambrx公司 | 包括非天然氨基酸的方法和组合物 |
| CA2882445A1 (en) * | 2005-12-14 | 2007-06-21 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| EP2213733A3 (en) | 2006-05-24 | 2010-12-29 | Novo Nordisk Health Care AG | Factor IX analogues having prolonged in vivo half life |
| MX2008016169A (es) | 2006-07-07 | 2009-01-15 | Novo Nordisk Healthcare Ag | Nuevos conjugados de proteina y metodos para su preparacion. |
| US9133495B2 (en) | 2006-09-08 | 2015-09-15 | Ambrx, Inc. | Hybrid suppressor tRNA for vertebrate cells |
| EP2615108B1 (en) | 2006-09-08 | 2016-10-26 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and thier uses |
| WO2008030614A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Suppressor trna transcription in vertebrate cells |
| CA2666426A1 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | Il-21 variants |
| US7902332B2 (en) | 2006-11-30 | 2011-03-08 | General Electric Company | Fluorine-labeled compounds |
| CA2670618C (en) | 2006-12-15 | 2016-10-04 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
| CN104163864B (zh) | 2007-03-30 | 2017-08-01 | Ambrx公司 | 经修饰fgf‑21多肽和其用途 |
| WO2008137471A2 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| US8946148B2 (en) | 2007-11-20 | 2015-02-03 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| SG188143A1 (en) | 2008-02-08 | 2013-03-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
| JPWO2009113578A1 (ja) * | 2008-03-13 | 2011-07-21 | 味の素株式会社 | カルボニル化合物除去材 |
| NZ600382A (en) | 2008-07-23 | 2013-11-29 | Ambrx Inc | Modified bovine G-CSF polypeptides and their uses |
| HUE035168T2 (en) | 2008-09-26 | 2018-05-02 | Ambrx Inc | Modified animal erythropoietin polypeptides and their applications |
| EA201170493A1 (ru) | 2008-09-26 | 2011-10-31 | Амбркс, Инк. | Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот |
| HRP20161055T1 (hr) * | 2009-03-20 | 2016-11-04 | Hanmi Science Co., Ltd. | Postupak proizvodnje konjugata specifičnog za mjesto od fiziološki djelotvornog polipeptida |
| US8067526B2 (en) | 2009-03-27 | 2011-11-29 | Nof Corporation | Method for producing polyoxalkylene derivative |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| WO2011017055A2 (en) * | 2009-07-27 | 2011-02-10 | Baxter International Inc. | Blood coagulation protein conjugates |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| NZ597600A (en) | 2009-07-27 | 2014-05-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
| ES2856055T3 (es) | 2009-07-27 | 2021-09-27 | Baxalta GmbH | Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre |
| EP2805965A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
| CN102753573A (zh) | 2009-12-21 | 2012-10-24 | Ambrx公司 | 经过修饰的牛促生长素多肽和其用途 |
| CA2791841C (en) | 2010-03-05 | 2023-01-03 | Rigshospitalet | Chimeric inhibitor molecules of complement activation |
| WO2011143274A1 (en) | 2010-05-10 | 2011-11-17 | Perseid Therapeutics | Polypeptide inhibitors of vla4 |
| SI3572091T1 (sl) | 2010-08-17 | 2024-07-31 | Ambrx, Inc., | Modificirani polipeptidi relaksina in njihova uporaba |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
| US8409526B2 (en) | 2010-12-09 | 2013-04-02 | General Electric Company | Cellulose substrates, compositions and methods for storage and analysis of biological materials |
| WO2012087838A1 (en) | 2010-12-22 | 2012-06-28 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
| CN103930440A (zh) | 2011-07-01 | 2014-07-16 | 拜耳知识产权有限责任公司 | 松弛素融合多肽及其用途 |
| US9738724B2 (en) | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| ES2611788T3 (es) | 2012-06-26 | 2017-05-10 | Sutro Biopharma, Inc. | Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso |
| HRP20190878T1 (hr) | 2012-08-31 | 2019-07-26 | Sutro Biopharma, Inc. | Modificirane aminokiseline koje sadrže azidnu grupu |
| ES2658039T3 (es) | 2013-07-10 | 2018-03-08 | Sutro Biopharma, Inc. | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
| WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| WO2015179734A1 (en) * | 2014-05-23 | 2015-11-26 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
| SMT202100388T1 (it) | 2014-10-24 | 2021-09-14 | Bristol Myers Squibb Co | Polipeptidi fgf-21 modificati e loro usi |
| BR112019016139A2 (pt) | 2017-02-08 | 2020-04-07 | Bristol-Myers Squibb Company | polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo |
| PL3849614T3 (pl) | 2018-09-11 | 2024-04-22 | Ambrx, Inc. | Koniugaty polipeptydu interleukiny-2 i ich zastosowania |
| CN113366015A (zh) | 2018-10-19 | 2021-09-07 | Ambrx公司 | 白细胞介素-10多肽缀合物、其二聚体及其用途 |
| WO2020168017A1 (en) | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| AU2021233909A1 (en) | 2020-03-11 | 2022-09-29 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
| EP4199968A1 (en) | 2020-08-20 | 2023-06-28 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
| MX2023011480A (es) | 2021-04-03 | 2023-12-06 | Ambrx Inc | Conjugados anticuerpo anti-her2-fármaco y usos de estos. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ244778A (en) * | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
| NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| WO1994025071A1 (en) * | 1993-05-05 | 1994-11-10 | Keith Rose | Polyoxime compounds and their preparation |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
-
1995
- 1995-11-09 EP EP95944855A patent/EP0788375A2/en not_active Withdrawn
- 1995-11-09 CA CA002204726A patent/CA2204726A1/en not_active Abandoned
- 1995-11-09 WO PCT/IB1995/001175 patent/WO1996041813A2/en not_active Ceased
-
1996
- 1996-11-09 AU AU73272/96A patent/AU7327296A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2204726A1 (en) | 1996-12-27 |
| WO1996041813A3 (en) | 1997-05-22 |
| EP0788375A2 (en) | 1997-08-13 |
| WO1996041813A2 (en) | 1996-12-27 |
| AU7327296A (en) | 1997-01-09 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
| 17P | Request for examination filed |
Effective date: 19970609 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
| AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 20000317 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20000728 |